首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   87篇
  免费   3篇
耳鼻咽喉   1篇
儿科学   4篇
妇产科学   2篇
基础医学   11篇
口腔科学   7篇
临床医学   9篇
内科学   32篇
神经病学   5篇
外科学   2篇
预防医学   10篇
药学   2篇
中国医学   4篇
肿瘤学   1篇
  2021年   1篇
  2020年   2篇
  2019年   1篇
  2018年   2篇
  2017年   2篇
  2014年   6篇
  2013年   1篇
  2012年   7篇
  2011年   7篇
  2010年   4篇
  2009年   4篇
  2008年   9篇
  2007年   10篇
  2006年   5篇
  2005年   10篇
  2004年   7篇
  2003年   7篇
  2002年   3篇
  2001年   1篇
  1991年   1篇
排序方式: 共有90条查询结果,搜索用时 647 毫秒
1.
A national survey of patients with hemophilia and other congenital bleeding disorders in Thailand was conducted in the years 2000 to 2002. Questionnaires were sent to physicians working at hospitals throughout the country. Although the overall response rate to the questionnaires was 19%, the two highest rates of 80% and 73.7% were found at university and regional hospitals, respectively, where most of the patients received their diagnosis and treatment. A total of 1,450 patients comprised of hemophilia 1,325 cases, von Willebrand disease, 69 cases, congenital factor VII deficiency, 15 cases, hereditary platelet dysfunction, 22 cases, and undefined causes of congenital bleeding disorders, 19 cases. Most were pediatric patients <15 years of age. Treatment was mainly given on demand for a bleeding episode, while only 8.6% received additional home treatment for early bleeding episodes. Replacement therapy primarily relied on fresh frozen plasma, cryoprecipitate and cryo-removed plasma. Factor concentrate was seldom used because of the high price. As a result, hemophilia care services in Thailand should be strengthened by providing comprehensive education for medical personnel, making available simple laboratory kits to determine hemophilia A and B, ensuring an adequate supply of blood components and affordable factor concentrate, and establishing home care treatment.  相似文献   
2.
The cost-effectiveness of carrier detection and prenatal diagnosis for hemophilia at the International Hemophilia Training Center, Bangkok, Thailand was studied. From 1991 to 2002, 209 females from 124 families with hemophilia A and B were included. There were 180 hemophilia A carriers and 29 hemophilia B carriers which could be classified into 78 obligate and 131 possible carriers. The phenotypic analysis for possible carriers involved the determination of levels of factor VIII or IX clotting activity (FVIII:C, FIX:C) and the ratio of FVIII:C and von Willebrand factor antigen. The result revealed that 49 females (37.4%) were diagnosed as carriers, 65 females (49.6%) were normal and 17 females (13%) were undetermined. Additional genotypic analysis was provided to 46 families with 74 females with obligate, proven or undetermined carriers within the reproductive life. The polymorphisms associated with factor VIII and IX genes were used including Bcl I for the factor VIII gene and combined use of Mse I, Sal I, Nru I, Hha I and Dde I for the factor IX gene. The informative rate was 59.4% (44/74). Consequently, 12 prenatal diagnoses for fetus at risk were performed. Sex determination was initially determined and followed by the diagnosis of hemophilia through informative gene tracking and/or the measurement of fetal levels of FVIII:C or FIX:C. The result revealed that 3 male fetuses were affected. The total cost of carrier detection and prenatal diagnosis that the families had to pay in the government hospital was 238,600 Baht (US dollars 5,965). It was compared to the estimated cost of minimal replacement therapy using lyophilized cryoprecipitate for the survival time of 30 years in one patient with hemophilia of 1,012,500 Baht (US dollars 25,312.5). The cost of prevention was much less than the replacement therapy. In conclusion, it is cost-effective to establish the service for carrier detection and prenatal diagnosis for hemophilia especially in developing countries with limited health resources.  相似文献   
3.
Maternal serum screening has gained widespread acceptance as a major prenatal screening tool for chromosomal abnormalities in the US and Europe since Merkatz et al described an association between low maternal serum alpha fetoprotein (AFP) levels and increased risk for trisomy 21 in 1984. In 1988, Wald et al proposed a screening program based on maternal age in combination with three biochemical markers--AFP, hCG and unconjugated estriol. This study from January 1996--September 2002 included 1,793 pregnant women (between 14-22 weeks gestation) which were divided into 2 groups--1,083 women > 35 years (60.40%) and 710 women < 35 years (39.60%). A second trimester risk for trisomy 21 > 1 : 270 was considered a positive screen and genetic counseling to discuss risks and benefits of amniocentesis was offered. This study had 1,376 cases (76.7%) with negative screening (not increased risk for DS and NTD), 21 (1.2%) with negative screening (not increased risk for DS only) ; 292 (16.3%) with increased risk for DS; 5 cases (0.3%) with increased risk for DS and elevated AFP; 19 cases (1.1%) with elevated AFP; 33 cases (1.8%) with previous DS only; and 9 cases (0.5%) with previous NTD only. Two percent (2.1%) of the results could not be interpreted either because the test was done too early, too late or were grand multiple pregnancies. This study demonstrated that multiple marker screening offers another option for older women who traditionally have all been considered candidates for amniocentesis.  相似文献   
4.
We studied cross-reactive antibodies against avian influenza H5N1 and 2009 pandemic (p) H1N1 in 200 serum samples from US military personnel collected before the H1N1 pandemic. Assays used to measure antibodies against viral proteins involved in protection included a hemagglutination inhibition (HI) assay and a neuraminidase inhibition (NI) assay. Viral neutralization by antibodies against avian influenza H5N1 and 2009 pH1N1 was assessed by influenza (H5) pseudotyped lentiviral particle-based and H1N1 microneutralization assays. Some US military personnel had cross-neutralizing antibodies against H5N1 (14%) and 2009 pH1N1 (16.5%). The odds of having cross-neutralizing antibodies against 2009 pH1N1 were 4.4 times higher in subjects receiving more than five inactivated whole influenza virus vaccinations than those subjects with no record of vaccination. Although unclear if the result of prior vaccination or disease exposure, these pre-existing antibodies may prevent or reduce disease severity.Outbreaks of 1997 avian influenza H5N1 and 2009 pandemic (p) H1N1 in humans have provided an opportunity to gain insight into cross-reactive immunity. The US military periodically collects and stores serum samples from service members linked to medical records.1 We measured cross-reactive antibodies in stored serum to avian influenza H5N1 and 2009 pH1N1 from US military personnel and identified factors associated with presence of neutralizing antibodies.Two hundred archived serum samples were obtained from the US Department of Defense Serum Repository. They were representative of a wide cross-section of active military personnel at the times of collection, whereas specific geographic information was not available on the individual selected; the cohort represents the general US military population, which is deployed throughout the United States and globally. Fifty samples each were selected from four birth cohorts: (1) < 1949, (2) 1960–1965, (3) 1966–1971, and (4) 1972–1977. Within each cohort, 25 samples were collected in the year 2000 (before the introduction of intranasal live attenuated influenza vaccine [LAIV]), and 25 samples were collected in 2008 (where 51% of donors had received LAIV). It has been suggested that LAIV elicits cross-reactive immunity.2,3 The samples were all collected before the outbreak of 2009 pH1N1, and there have not been any reported outbreaks of H5N1 in US military personnel.Assays used to measure antibodies included a hemagglutination inhibition (HI) assay and a neuraminidase inhibition (NI) assay.4 Viral neutralization by antibodies against H5N1 and 2009 pH1N1 was assessed by influenza (H5) pseudotyped lentiviral particle-based (H5pp)5 and microneutralization assays, respectively. Electronic medical and vaccination records from the Defense Medical Surveillance System (DMSS), which captured records before the serum sample date, were linked to samples and compared with the in vitro results.1The odds ratios (ORs) and 95% confidence intervals (95% CIs) of univariate and multivariate binary logistic regression analyses were used to determine the association between donor characteristics and positive antibody responses. A multiple logistic regression model was constructed, and it included independent variables with a P value of < 0.05 in univariate logistic regression. A P value of < 0.05 was considered to indicate statistical significance. SPSS 12.0 for Windows (SPSS Inc., Chicago, IL) was used to perform all statistical analysis.Cross-reactivity is summarized in 5 and 22.5% for the NI assay. H5pp and NI antibody titers to H5N1 were evenly distributed among birth cohorts and did not differ substantially based on history of vaccination or prior respiratory infections. Of those individuals with neutralizing antibodies to H5N1 (N = 28), 32.1% also had neutralizing antibodies to pH1N1, whereas 19.3% of those individuals with any H5N1-specific antibody response also had neutralizing antibodies to pH1N1 (
Characteristics (n)H5N12009 pH1N1§
HI assay* % positive (GM titer)H5pp % positive (GM titer)NI assay % positive (GM titer)HI assay % positive (GM titer)Neutralization % positive (GM titer)NI assay % positive (GM titer)
Total
 2000.5 (5.1)14.0 (21.4)22.5 (121.6)5.5 (7.1)16.5 (20.4)9.0 (92.8)
Birth cohort
 1936–1949 (50)2.0 (5.3)18.0 (22.0)24.0 (126.0)6.0 (7.3)16.0 (19.5)12.0 (97.6)
 1960–1965 (50)0.0 (5.0)16.0 (20.3)26.0 (129.6)6.0 (7.7)30.0 (27.5)6.0 (90.3)
 1966–1971 (50)0.0 (5.0)12.0 (23.3)20.0 (117.9)10.0 (8.0)16.0 (23.6)10.0 (92.2)
 1972–1977 (50)0.0 (5.3)10.0 (20.0)20.0 (113.7)0.0 (5.7)4.0 (13.6)8.0 (91.5)
Serum collection year
 Y2000 (100)0.0 (5.1)15.0 (21.7)21.0 (120.3)7.0 (7.3)16.0 (20.6)11.0 (94.5)
 Y2008 (100)1.0 (5.2)13.0 (21.1)24.0 (123.0)4.0 (7.0)17.0 (20.1)7.0 (91.2)
Sex
 Female (32)3.1 (5.7)21.9 (26.3)12.5 (102.4)3.1 (6.9)12.5 (19.2)6.3 (96.7)
 Male (168)0.0 (5.0)12.5 (20.5)24.4 (125.7)6.0 (7.2)17.3 (20.6)9.5 (92.1)
Any cross-reactive antibody to
 H5N1 (57)8.8 (8.9)19.3 (25.2)22.8 (119.9)
 pH1N1 (45)2.2 (5.3)28.9 (31.2)37.8 (165.2)
Neutralizing antibodies to
 H5N1 H5pp (28)10.7 (9.5)32.1 (33.6)25.0 (116.9)
 2009 pH1N1 neutralization (33)3.0 (5.4)27.3 (28.9)30.3 (140.3)
Lifetime seasonal vaccinations
 No record (66)0.0 (5.1)10.6 (20.2)27.7 (128.1)7.6 (7.4)15.2 (20.6)12.1 (96.5)
 1–5 vaccinations (88)1.1 (5.2)15.9 (21.5)17.0 (109.2)5.7 (7.1)17.0 (20.5)6.8 (89.1)
  > 5 vaccinations (46)0.0 (5.1)15.2 (22.2)32.6 (138.8)2.2 (6.8)17.4 (19.7)8.7 (95.0)
Time since last vaccine
 No record (66)0.0 (5.1)10.6 (20.2)22.7 (128.1)7.6 (7.4)15.2 (20.6)12.1 (96.5)
  ≤ 1 year (96)0.0 (5.1)15.6 (21.5)24.0 (120.7)4.2 (7.1)19.8 (21.0)8.3 (91.2)
 > 1 year (38)2.6 (5.3)15.8 (22.4)18.4 (113.4)5.2 (6.8)10.5 (18.3)5.3 (90.6)
Vaccination history lifetime (at least one dose)
 No record of vaccination (66)0.0 (5.1)10.6 (20.2)22.7 (128.1)7.6 (7.4)15.2 (20.6)12.1 (96.5)
 Inactivated whole virus (71)0.0 (5.0)14.1 (20.4)22.5 (115.7)2.8 (6.4)15.5 (19.6)5.6 (87.1)
 Split type (102)1.0 (5.0)15.7 (20.4)21.6 (115.7)4.9 (6.4)19.6 (19.6)6.9 (87.1)
 Influenza vaccine not otherwise specified (16)0.0 (5.2)12.5 (27.9)37.5 (166.4)0.0 (6.2)6.3 (16.1)12.5 (102.3)
 Live attenuated intranasal (50)0.0 (5.1)10.0 (18.8)20.0 (112.2)4.0 (7.0)18.0 (20.3)4.0 (85.2)
History of respiratory illness
 No record of illness (119)0.0 (5.0)10.1 (18.5)18.5 (112.6)4.2 (7.0)15.1 (20.5)8.4 (90.7)
 Influenza-like illness (4)0.0 (5.0)25.0 (20.7)0.0 (80.0)0.0 (8.4)25.0 (28.3)25.0 (100.2)
 Upper respiratory infection (65)1.5 (5.4)23.1 (29.3)27.7 (135.0)7.7 (7.3)18.5 (20.7)9.2 (93.1)
 Lower respiratory infection (37)2.7 (5.6)18.9 (30.2)35.1 (157.6)8.1 (8.1)21.6 (22.4)13.5 (108.4)
 Respiratory illness past year (28)0 (5.1)25.0 (25.1)32.1 (154.9)7.1 (8.0)28.6 (24.4)3.6 (86.3)
Open in a separate windowTiters with a value of zero (below the detection limit) were assigned a value of five for calculation of geometric means (GMs).*H5N1, A/Vietnam/1203/2004; positive titer ≥ 40.H5 hemagglutinin (A/Cambodia/408008/05) pseudotyped lentiviral particle; positive titer ≥ 160.Reassortant H1N1 (HA, PB1, PB2, PA, NP, and M from H1N1 [A/PR/8/34]; N1 from H5N1 [A/Vietnam/DT-036/2005]); positive titer ≥ 160.§2009 H1N1, A/California/04/2009; same positive titer cutoffs as for H5N1.As with H5N1, samples with positive HI titers were low for 2009 pH1N1 at 5.5%, whereas neutralizing antibody titers were higher, with 16.5% positive in the microneutralization assay but only 9% positive in the NI assay. Positive neutralization titers were less evenly distributed among birth cohorts, with only 4% positive in the 1972–1977 birth cohort, whereas 30% were positive in the 1960–1965 cohort. Like H5N1, positive antibody titers to 2009 pH1N1 did not differ substantially based on history of vaccination or prior respiratory infections. Of those individuals with neutralizing antibodies to pH1N1 (N = 33), 27.3% also had neutralizing antibodies to H5N1, whereas 28.9% of those individuals with any pH1N1-specific antibody response also had neutralizing antibodies to H5N1.Univariate associations between the prevalence of cross-reactive antibodies to H5N1 and 2009 pH1N1 and independent variables, including year of birth, serum collection year, sex, and seasonal influenza vaccination history, are shown in Characteristic (n)2009 pH1N1H5N1PrevalenceOR (95% CI)Adjusted OR (95% CI)PrevalenceOR (95% CI)Positive neutralizing antibody33 (16.5%)28 (14.0%)Serum collection year 2000 (100)16 (16.0%)ReferenceReference15 (15.0%)Reference 2008 (100)17 (17.0%)1.1 (0.5–2.3)0.7 (0.3–1.8)13 (13.0%)0.9 (0.4–1.9)Birth cohort 1936–1949 (50)8 (16.0%)4.6 (0.9–22.7)5.3 (1.0–27.0)9 (18.0%)2.0 (0.6–6.4) 1960–1965 (50)15 (30.0%)10.3 (2.2–47.9)11.0 (2.3–52.9)8 (16.0%)1.7 (0.5–5.7) 1966–1971 (50)8 (16.0%)4.6 (0.9–22.7)5.1 (1.0–26.2)6 (12.0%)1.2 (0.4–4.3) 1972–1977 (50)2 (4.0%)ReferenceReference5 (10.0%)ReferenceSex Female (32)4 (12.5%)Reference7 (21.9%)Reference Male (168)29 (17.3%)1.5 (0.5–4.5)21 (12.5%)0.5 (0.2–1.3)Positive neutralizing antibody titers H5pp (57)11 (19.3%)1.3 (0.6–2.9) pH1N1 (45)13 (28.9%)3.8 (1.6–8.7)Vaccination record Number of seasonal influenza vaccinations  No record (66)10 (15.2%)Reference7 (10.6%)Reference  1–5 vaccinations (88)15 (17.0%)1.2 (0.5–2.8)14 (15.9%)1.6 (0.6–4.2)  > 5 vaccinations (46)8 (17.4%)1.2 (0.4–3.3)7 (15.2%)1.5 (0.5–4.7) Time since last vaccination  No record (66)10 (15.2%)Reference7 (10.61%)Reference   ≤ 1 year (96)19 (19.8%)1.4 (0.6–3.2)15 (15.6%)1.6 (0.6–4.1)  > 1 year (33)4 (10.5%)0.7 (0.2–2.3)6 (15.8%)1.6 (0.5–5.1) Number of inactivated whole virus vaccinations  No record (129)22 (17.1%)ReferenceReference18 (14.0%)Reference  1–5 vaccinations (53)4 (7.5%)0.4 (0.1–1.2)0.4 (0.1–1.4)7 (13.2%)0.9 (0.4–2.4)  > 5 vaccinations (18)7 (38.9%)3.1 (1.1–8.9)4.4 (1.3–15.6)3 (16.7%)1.2 (0.3–4.7) Time since last inactivated whole virus vaccination  No record (129)22 (17.1%)Reference18 (14.0%)Reference   ≤ 1 year (19)4 (21.1%)1.3 (0.4–4.3)3 (15.8%)1.2 (0.3–4.4)  > 1 year (52)7 (13.5%)0.8 (0.3–1.9)7 (13.5%)1.0 (0.4–2.5) Number of split type vaccinations  No record (98)13 (13.3%)Reference12 (12.2%)Reference  1–5 vaccinations (94)19 (20.2%)1.7 (0.8–3.6)14 (14.9%)1.3 (0.6–2.9)  > 5 vaccinations (8)1 (12.5%)0.9 (0.1–8.2)2 (25.0%)2.4 (0.4–13.2) Time since last split type vaccination  No record (98)13 (13.3%)Reference12 (12.2%)Reference   ≤ 1 year (44)10 (22.7%)1.9 (0.8–4.8)10 (22.7%)2.1 (0.8–5.3)  > 1 year (58)10 (17.2%)1.4 (0.6–3.3)6 (10.3%)0.8 (0.3–2.3) Number of intranasal LAIV vaccinations  No record (150)24 (16.0%)Reference23 (15.3%)Reference  1–5 vaccinations (50)9 (18.0%)1.2 (0.5–2.7)5 (10%)0.6 (0.2–1.7) Time since last intranasal LAIV vaccination  No record (150)24 (16.0%)Reference23 (15.3%)Reference   ≤ 1 year (34)7 (20.6%)1.4 (0.5–3.5)3 (8.8%)0.5 (0.2–1.9)  > 1 year (16)2 (12.5%)0.8 (0.2–3.5)2 (12.5%)0.8 (0.2–3.7)Open in a separate windowTo the best of our knowledge, the present study is the first report of cross-reactive antibodies to both H5N1 and 2009 pH1N1 in a US military population. Cross-reactive antibodies to both influenza viruses were common in this population. Most serum samples (86%) positive in the H5N1 neutralization assay had no detectable HI activity (titer ≥ 10), whereas 94% of samples that neutralized 2009 pH1N1 also had detectable HI activity (titer ≥ 10; data not shown). In addition, cross-reactive antibodies to avian influenza H5N1 were not necessarily accompanied by cross-reactive antibodies to 2009 pH1N1. Taken together, these findings suggest that the observed cross-reactive neutralization against the two influenza viruses was caused by different antibodies in serum samples.This report is also the first report to associate history of receiving more than five doses of inactivated whole influenza virus vaccine with neutralizing antibodies against 2009 pH1N1. This finding suggests a protective advantage of repeated vaccination with seasonal whole virus vaccine, generating cross-reactive antibodies against previously unencountered strains. It has been suggested that the high immunogenicity of the inactivated whole virus vaccine is partly caused by the adjuvant effect of the viral RNA presented, stimulating innate immunity through the Toll-like receptor (TLR) 7-dependent pathway.6 We hypothesize that the combined effect of adjuvant activity and the heterogenous mix of flu strains that an individual would be exposed to over the course of multiple seasonal vaccinations may enhance the breadth of antibody response and promote the generation of cross-reactive antibodies.A retrospective case-control study conducted in US military personnel after the outbreak of 2009 pH1N1 showed that both 2008–2009 seasonal influenza vaccine and history of seasonal vaccine in the prior 4 years afforded some protection against pH1N1. Vaccine effectiveness (VE) was high in persons ≥ 40 (55%) or < 25 (50%) years of age but very low in persons 25–39 years of age (< 10%).7 These findings correlate with the high levels of cross-reactive 2009 pH1N1 antibodies reported here, with 30% in the 1960–1965 cohort (age range = 35–48) but only 4% in the 1972–1977 cohort (age range = 23–36). Our findings are similar to the results found recently in an elderly population in the United States.8 The exception is in those individuals born before 1950, in whom antibody responses were much higher in this cohort. Both our study and the US study differ from two recent seroprevalence studies in Singapore and China, where cross-reactive antibodies were rare in various age groups.9,10 High seasonal influenza vaccination rates in US military personnel found here and prior studies11 may explain the differences observed in these populations, although results from small retrospective seroprevalence studies should be interpreted cautiously. Possible alternative explanations include differences in laboratory assay methods, natural influenza exposure in the sampled populations, and/or use of convenience sampling methods.Studies in humans suggest that the antibody to influenza neuraminidase is associated with resistance to influenza.12 A recent serological study in a small number of human serum samples showed that 24% had cross-reactive antibodies to avian N1,13 similar to our findings (22.5%). In addition, we observed that 9% of serum samples had cross-reactive antibodies to pH1N1.Like pH1N1, persons < 40 years old seem to be most affected by H5N1 infection, with infection rarer in older individuals.14 However, we did not find a difference in cross-reactive antibody prevalence to either neuraminidase or neutralizing antibodies (H5pp) with year of birth or other immunologic markers of exposure, including vaccination history or prior respiratory illness.A possible limitation of our study is that the DMSS may not have captured all relevant medical encounter and/or vaccination data, particularly for encounters that were not entered into the system electronically or coded accurately. Data in the DMSS are provider-dependent, and the DMSS captures data from various historical time periods, dating back to 1980 for immunization data, 1985 for Department of Defense Serum Repository specimens, 1990 for demographic data, and only 1996 for outpatient data. Interpretation of data presented on history of respiratory illness, which is entirely dependent on voluntary provider reporting and International Classification of Diseases (ICD-9) coding, is particularly limited by lack of virologic confirmation.Cross-reactive immunity to pathogenic influenza strains was found in a subset of US military service members, and it may serve to prevent or reduce the severity of influenza. A better understanding of the mechanisms underlying the development of cross-reactive antibodies will aid in the development of more effective preventive and therapeutic measures.  相似文献   
5.
Linkages to HIV confirmatory testing and antiretroviral therapy after online,supervised, HIV self‐testing among Thai men who have sex with men and transgender women     
Nittaya Phanuphak  Jureeporn Jantarapakde  Linrada Himmad  Thanthip Sungsing  Ratchadaporn Meksena  Sangusa Phomthong  Petchfa Phoseeta  Sumitr Tongmuang  Pravit Mingkwanrungruang  Dusita Meekrua  Supachai Sukthongsa  Somporn Hongwiangchan  Nutchanin Upanun  Supunnee Jirajariyavej  Tanate Jadwattanakul  Supphadith Barisri  Tippawan Pankam  Praphan Phanuphak 《Journal of the International AIDS Society》2020,23(1)
  相似文献   
6.
Effects of Compliant Flooring on Dynamic Balance and Gait Characteristics of Community-dwelling Older Persons     
Sittichoke  C.  Buasord  J.  Boripuntakul  S.  Sungkarat  Somporn 《The journal of nutrition, health & aging》2019,23(7):665-668
The journal of nutrition, health & aging - Compliant flooring while providing the impact force attenuation in the event of falls, its low stiffness characteristic might impair balance and gait...  相似文献   
7.
Roseomonas gilardii subsp rosea, a pink bacterium associated with bacteremia: the first case in Thailand     
Srifuengfung S  Tharavichitkul P  Pumprueg S  Tribuddharat C 《The Southeast Asian journal of tropical medicine and public health》2007,38(5):886-891
Roseomonas is a pink-pigmented, non-fermentative, gram-negative coccobacillus bacterium. Human infections caused by Roseomonas are very rare. We report the first case of bacteremia associated with Roseomonas gilardii subsp rosea in Thailand. The bacterium was isolated from blood culture and identified by cellular morphology, characteristics of colonies on blood agar, extensive biochemical tests and 16S ribosomal DNA sequencing.  相似文献   
8.
Argininosuccinate synthetase deficiency: mutation analysis in 3 Thai patients     
Wasant P  Viprakasit V  Srisomsap C  Liammongkolkul S  Ratanarak P  Sathienkijakanchai A  Svasti J 《The Southeast Asian journal of tropical medicine and public health》2005,36(3):757-761
Remarkable improvements in public health, nutrition, hygiene, and availability of medical services in the last 20 years have significantly reduced infant and childhood mortality in Thailand. Therefore, many rare and previously unidentified genetic disorders, which, in the past, usually led to the death of affected infants before a definitive diagnosis, have now been increasingly recognized. Recently, we identified three unrelated patients from Thailand who suffered from citrullinemia, one of five inherited types of urea cycle disorders. All were diagnosed within their first few weeks of life. Biochemical analyses, including plasma amino acid and urine organic acid profiles, are consistent with argininosuccinate synthetase (ASS) deficiency. Extensive mutation study by direct genomic sequencing of ASS demonstrated a homozygous G117S mutation in one patient and homozygous R363W mutations in the other two families.  相似文献   
9.
Incidence and risk factors of parenteral nutrition‐associated liver disease in newborn infants     
Photchanaphorn Koseesirikul  Somporn Chotinaruemol  Nuthapong Ukarapol 《Pediatrics international》2012,54(3):434-436
Background: The aim of the present study was to determine the incidence and risk factors of parenteral nutrition‐associated liver disease (PNALD) in neonates. Methods: A 1 year prospective cohort study was carried out at the neonatal intensive care unit and sick neonatal wards, Chiang Mai University Hospital. Newborns >1000 g, receiving >7 days of parenteral nutrition (PN), were enrolled. Liver function tests were done by the end of first, second, and fourth week, and then every 4 weeks until the PN was discontinued and the jaundice resolved. The diagnosis of PNALD relied on a history of PN, direct bilirubin >2 mg/dL, and exclusion of other causes of neonatal cholestasis. Selected patient factors and PN compositions were analyzed to determine the risks for development of PNALD. Results: A total of 24 infants with a mean gestational age and birthweight of 32.5 weeks and 1840 g were enrolled. Eight of the 24 developed PNALD. Compared to those without PNALD, gastrointestinal surgery, duration of enteral starvation, duration of PN, maximum PN caloric intake, and maximum carbohydrate intake were significantly associated with the development of liver disease. Despite the lack of statistical significance, there was a trend towards cholestasis in patients with sepsis. Elevation of direct bilirubin was the earliest biochemical change, observed in the first week after PN, followed by increased transaminases. Conclusion: Gastrointestinal surgery, duration of enteral starvation, duration of PN, maximum caloric and carbohydrate intake in PN were significant risks of PNALD in newborn infants.  相似文献   
10.
Preparation of acrylic grafted chitin for wound dressing application   总被引:1,自引:0,他引:1  
Tanodekaew S  Prasitsilp M  Swasdison S  Thavornyutikarn B  Pothsree T  Pateepasen R 《Biomaterials》2004,25(7-8):1453-1460
Chitin grafted with poly(acrylic acid) (chitin-PAA) was prepared with the aim of obtaining a hydrogel characteristic for wound dressing application. The chitin-PAA films were synthesized at various acrylic acid feed contents to investigate its effect on water sorption ability. Acrylic acid (AA) was first linked to chitin, acting as the active grafting sites on the chain that was further polymerized to form a network structure. The evidences of grafting were found from FTIR and solid state 13C NMR spectra. The TGA results exhibited the high degradation temperature of the grafted product suggesting the formation of a network structure. The degree of swelling (DS) of chitin-PAA films was found in the range of 30-60 times of their original weights depending upon the monomer feed content. The chitin-PAA film with 1:4 weight ratio of chitin:AA, possessed optimal physical properties. The cytocompatibility of the film was investigated with a cell line of L929 mouse fibroblasts. The morphology and behavior of the cells on the chitin-PAA film were determined after different time periods of culture up to 14 days. The L929 cells proliferated and attached well onto the film. These results suggested that the 1:4 chitin-PAA has a potential to be used as a wound dressing.  相似文献   
1 [2] [3] [4] [5] [6] [7] [8] [9] 下一页 » 末  页»
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号